The safety and antibody response of the nasal COV2 vaccine against the SARS-CoV-2 virus

2023-509725-49-00 Protocol COV2FIN11 Human pharmacology (Phase I) - First administration to humans Ended

Start 27 Jan 2025 · End 6 Aug 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol COV2FIN11

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 50
Countries 1
Sites 1

Booster immunisation against COVID-19 disease caused by SARS-CoV-2 virus

Key facts

Sponsor
Rokote Laboratories Finland Oy
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
27 Jan 2025 → 6 Aug 2025
Decision date (initial)
2024-11-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-509725-49-00
WHO UTN
U1111-1299-1228
ClinicalTrials.gov
NCT06851611

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Booster immunisation against COVID-19 disease caused by SARS-CoV-2 virus

VersionLevelCodeTermSystem organ class
25.1 LLT 10087820 Vaccination booster dose 100000004848
28.0 LLT 10087820 Vaccination booster dose 100000004848
28.0 LLT 10084462 SARS-CoV-2 vaccination 100000004865

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Rokote Laboratories Finland Oy

Sponsor organisation
Rokote Laboratories Finland Oy
Address
Microkatu 1
City
Kuopio
Postcode
70210
Country
Finland

Scientific contact point

Organisation
Rokote Laboratories Finland Oy
Contact name
CEO

Public contact point

Organisation
Rokote Laboratories Finland Oy
Contact name
CEO

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ended 50 1
Rest of world 0

Investigational sites

Finland

1 site · Ended
Pohjois-Savon hyvinvointialue
Kuopio University Hospital, Department of Otorhinolaryngology, Puijonlaaksontie 2, P. O. Box 1711, Kuopio

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2025-01-27 2025-08-06 2025-01-28 2025-06-26

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-18 Finland Acceptable with conditions
2024-11-04
2024-11-06
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-15 Finland Acceptable
2024-12-10
2024-12-11
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-01-27 Finland Acceptable
2024-12-10
2025-01-27
4 SUBSTANTIAL MODIFICATION SM-2 2025-02-13 Finland Acceptable
2025-03-12
2025-03-12
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-03-14 Finland Acceptable
2025-03-12
2025-03-14
6 NON SUBSTANTIAL MODIFICATION NSM-4 2025-06-11 Finland Acceptable
2025-03-12
2025-06-11
7 SUBSTANTIAL MODIFICATION SM-3 2025-06-25 Finland Acceptable
2025-08-05
2025-08-06